Exp Mol Med.  2009 Jun;41(6):417-428. 10.3858/emm.2009.41.6.047.

A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation

• Cho KH
• Kim JR

• KMID: 756234
• DOI: http://doi.org/10.3858/emm.2009.41.6.047

Abstract

It has been hypothesized that blood infusion of reconstituted HDL (rHDL) is a possible therapeutic strategy for the treatment of coronary artery disese. To compare short-term anti-inflammatory activity of wildtype (WT) apoA-I and point mutants, each rHDL containing WT, V156K, or R173C was infused into apo-E deficient atherosclerotic mice. Each rHDL was injected via the tail vein at a dosage of 120 mg/kg of body weight in 0.4 ml of tris-buffered saline (TBS), and blood was then collected at 24 and 48 h post-injection. Although regression activity was observed in each of the rHDL infused groups, a 30% reduction in the lipid-stained area of the aortic sinus was observed in the V156K and R173C-rHDL groups when compared to that of the WT-rHDL group, and this reduction was well correlated with an approximately 60% reduction in the accumulation of macrophages in the lesion area. Additionally, the groups that received the V156K and R173C-rHDL treatments showed smaller increases in the GOT, GPT, interleukin-6, myeloperoxidase (MPO) and lipid hydroperoxide (LPO) serum levels than those that received the WT-rHDL treatment. In addition, the strongest serum paraoxonase and ferric reducing ability was observed in the V156K and R173C-rHDL groups. In vitro nitration and chlorination of apoA-I by MPO treatment revealed that V156K-rHDL and R173C-rHDL were less susceptible to chlorination. Furthermore, rHDL treatment inhibited cellular uptake of oxidized LDL by macrophage cells and the production of proatherogenic species in culture media. In conclusion, blood infusions of the rHDLs exerted in vivo regression activity with anti-inflammatory and antioxidant activity in apo-E deficient mice and THP-1 cells, especially in those that were treated with V156K and R173C apoA-I.

Keyword

apolipoprotein A-I; apolipoproteins E; atherosclerosis; inflammation; lipoproteins, HDL

MeSH Terms

Animals
Anti-Inflammatory Agents/immunology/*therapeutic use
Apolipoprotein A-I/blood/genetics/immunology/*therapeutic use
Apolipoproteins E/genetics
Aryldialkylphosphatase/blood/metabolism
Atherosclerosis/*drug therapy
Cell Line
Cell Membrane Permeability
Cholesterol/blood/metabolism
Humans
Lipoproteins, HDL/genetics/immunology/*therapeutic use
Lipoproteins, LDL/metabolism
Macrophages/cytology
Mice
Mice, Inbred C57BL
Mice, Knockout
Oxidation-Reduction/*drug effects
Peroxidase/blood/metabolism
Point Mutation